Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
SPRY — ARS Pharmaceuticals, Inc.
NASDAQ
FULL STOCK PAGE →

Q2 2026 Earnings Call Summary

AUG 13, 2026
REVENUE
$33.7M +48.4%
NET MARGIN
-185.2% +82.1 PTS
EPS
-$0.63 -3.3%
FREE CASH FLOW
-$60.9M -35.6%

No summary has been written for this call yet.